Revenues of Arcus Biosciences, Inc. from 30 Sep 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Arcus Biosciences, Inc. quarterly and annual Revenues in USD history and change rate from 30 Sep 2017 to 30 Sep 2025.
  • Arcus Biosciences, Inc. Revenues for the quarter ending 30 Sep 2025 was $26,000,000, a 46% decline year-over-year.
  • Arcus Biosciences, Inc. Revenues for the twelve months ending 30 Sep 2025 was $240,000,000.
  • Arcus Biosciences, Inc. annual Revenues for 2024 was $258,000,000, a 121% increase from 2023.
  • Arcus Biosciences, Inc. annual Revenues for 2023 was $117,000,000, a 4.5% increase from 2022.
  • Arcus Biosciences, Inc. annual Revenues for 2022 was $112,000,000.
Source SEC data
View on sec.gov
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Change (%)
Revenues, Annual (USD)
Revenues, YoY Annual Change (%)

Arcus Biosciences, Inc. Quarterly Revenues (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $240,000,000 $26,000,000 -$22,000,000 -46% 01 Jul 2025 30 Sep 2025 10-Q 28 Oct 2025 2025 Q3
Q2 2025 $262,000,000 $160,000,000 +$121,000,000 +310% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $141,000,000 $28,000,000 -$117,000,000 -81% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $258,000,000 $26,000,000 01 Oct 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
Q3 2024 $48,000,000 01 Jul 2024 30 Sep 2024 10-Q 28 Oct 2025 2025 Q3
Q2 2024 $39,000,000 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $145,000,000 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2020 $77,517,000 $9,487,000 -$263,000 -2.7% 01 Oct 2020 31 Dec 2020 10-K 25 Feb 2021 2020 FY
Q3 2020 $77,780,000 $64,530,000 +$62,780,000 +3587% 01 Jul 2020 30 Sep 2020 10-K 25 Feb 2021 2020 FY
Q2 2020 $15,000,000 $1,750,000 $0 0% 01 Apr 2020 30 Jun 2020 10-K 25 Feb 2021 2020 FY
Q1 2020 $15,000,000 $1,750,000 $0 0% 01 Jan 2020 31 Mar 2020 10-K 25 Feb 2021 2020 FY
Q4 2019 $15,000,000 $9,750,000 +$8,188,000 +524% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $6,812,000 $1,750,000 -$2,541,000 -59% 01 Jul 2019 30 Sep 2019 10-K 25 Feb 2021 2020 FY
Q2 2019 $9,353,000 $1,750,000 +$500,000 +40% 01 Apr 2019 30 Jun 2019 10-K 25 Feb 2021 2020 FY
Q1 2019 $8,853,000 $1,750,000 +$500,000 +40% 01 Jan 2019 31 Mar 2019 10-K 25 Feb 2021 2020 FY
Q4 2018 $8,353,000 $1,562,000 +$312,000 +25% 01 Oct 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
Q3 2018 $8,041,000 $4,291,000 +$4,128,000 +2533% 01 Jul 2018 30 Sep 2018 10-K 05 Mar 2020 2019 FY
Q2 2018 $3,913,000 $1,250,000 01 Apr 2018 30 Jun 2018 10-K 05 Mar 2020 2019 FY
Q1 2018 $1,250,000 01 Jan 2018 31 Mar 2018 10-K 05 Mar 2020 2019 FY
Q4 2017 $1,250,000 01 Oct 2017 31 Dec 2017 10-K 05 Mar 2019 2018 FY
Q3 2017 $163,000 01 Jul 2017 30 Sep 2017 10-K 05 Mar 2019 2018 FY

Arcus Biosciences, Inc. Annual Revenues (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $258,000,000 +$141,000,000 +121% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
2023 $117,000,000 +$5,000,000 +4.5% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
2022 $112,000,000 01 Jan 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
2019 $15,000,000 +$6,647,000 +80% 01 Jan 2019 31 Dec 2019 10-K 05 Mar 2020 2019 FY
2018 $8,353,000 +$6,940,000 +491% 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
2017 $1,413,000 01 Jan 2017 31 Dec 2017 10-K 05 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.